ReviewOncology letters2026
Brain-derived neurotrophic factor in solid tumor angiogenesis and neurovascular-immune interactions (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain-derived neurotrophic factor (BDNF), a prototypical neurotrophin, together with its high-affinity receptor tropomyosin receptor kinase B (TrkB), regulates neuronal survival, synaptic plasticity and neurovascular unit homeostasis. Beyond the nervous system, BDNF and TrkB are aberrantly expressed in multiple solid tumors and have been implicated in proliferation, invasion, epithelial-mesenchymal transition, perineural invasion and resistance to therapy. Experimental evidence demonstrates direct vascular activity in selected settings: BDNF/TrkB promotes endothelial survival, migration and tube formation, mobilizes TrkB-positive progenitor cells and induces hypoxia-inducible factor-1α/vascular endothelial growth factor (VEGF)-dependent angiogenic programs in neuroblastoma, chondrosarcoma and hepatocellular carcinoma models. This direct evidence is concentrated in selected systems, whereas in other tumor types BDNF/TrkB is linked chiefly to tumor progression and neural or stromal remodeling that may secondarily shape vascular behavior. Within tumor cells, BDNF/TrkB integrates phosphoinositide 3-kinase/AKT, extracellular signal-regulated kinase, phospholipase Cγ and stress-responsive cascades to regulate angiogenic and inflammatory mediators, thereby linking malignant phenotypes to vascular and immune changes. The present review summarizes the molecular and physiological features of BDNF/TrkB, evaluates tumor-specific evidence within endothelial/progenitor, tumor-intrinsic and neurovascular-immune compartments and examines the potential value and limitations of tissue, circulating and multi-omics biomarkers. Potential intersections with VEGF-targeted therapy, Trk inhibitors and vascular normalization are discussed, together with the experimental and clinical gaps that must be addressed before BDNF/TrkB-directed strategies can be translated to patients with solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.